RGNX Stock Risk & Deep Value Analysis
Regenxbio Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About RGNX Stock
We analyzed Regenxbio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RGNX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
RGNX Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Upcoming Risk Events
- 📅
Negative outcome or delays in RGX-314 regulatory review/PDUFA
- 📅
Further clinical trial setbacks or additional FDA holds on other pipeline assets
- 📅
Unfavorable outcome or significant costs from the securities class action lawsuit
- 📅
Higher-than-expected cash burn leading to significant dilution through ATM program
Unlock RGNX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Regenxbio Inc (RGNX) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Visit Regenxbio Inc WebsiteInvestment Thesis
Regenxbio represents a high-risk, high-reward investment proposition. The bull case hinges on the successful FDA approval and commercialization of RGX-314 for wet AMD, supported by the AbbVie partnership, and positive clinical data from its broader NAV gene therapy pipeline, especially RGX-202. However, recent FDA clinical holds, an associated lawsuit, and earnings misses have significantly increased the risk profile, demanding careful monitoring of regulatory outcomes and financial health.
Is RGNX Stock Undervalued?
Unlock the full AI analysis for RGNX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
RGNX Price Targets & Strategy
12-Month Target
$27.80
Bull Case
$50.00
Bear Case
$12.00
Valuation Basis
Based on median analyst price targets reflecting discounted future cash flows from anticipated RGX-314 approval and commercialization.
Entry Strategy
Consider dollar-cost averaging in the $7-$9 range, seeking consolidation above recent lows. Monitor for positive resolution of regulatory concerns.
Exit Strategy
Take partial profits at $25-$30 (analyst median target range) to de-risk, with a stop-loss order below $7, given the heightened regulatory and legal risks.
Portfolio Allocation
3-5% for aggressive risk tolerance; not suitable for conservative or moderate portfolios at this stage.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is RGNX Financially Healthy?
Valuation
P/E Ratio
-2.30
Profitability
Net Margin
-113.80%
Return on Equity
-103.12%
Revenue Growth
104.60%
EPS
$-3.76
Balance Sheet
Cash & Equivalents
$240.90M
Does RGNX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable, but under scrutiny. While the IP is valuable, recent clinical holds challenge the perceived robustness and safety profile of the platform, potentially impacting its long-term competitive positioning.
Moat Sources
1 Identified
The proprietary NAV AAV platform provides a significant technological barrier and competitive edge in gene therapy. However, the durability is directly tied to the platform's clinical success and safety profile. Recent FDA holds introduce a material risk to this durability.
Moat Erosion Risks
- •Clinical trial failures or persistent safety concerns with the NAV AAV platform
- •Emergence of superior or safer gene therapy technologies from competitors
- •Patent expirations or challenges to intellectual property
- •Failure to gain regulatory approvals for key pipeline assets
RGNX Competitive Moat Analysis
Sign up to see competitive advantages
RGNX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bearish given recent negative news regarding FDA holds and the class action lawsuit.
Institutional Sentiment
Neutral to Negative. While institutional ownership is high (88.08%), recent analyst price target cuts post-Q4 earnings (H.C. Wainwright, Morgan Stanley, Stifel) indicate a deteriorating sentiment.
Insider Activity (Form 4)
No specific Form 4 filings reported for insiders (CEO/CFO or others) in the last 90 days, suggesting no recent buying or selling conviction from key executives.
Options Flow
Normal options activity; no specific unusual activity reported in the provided data.
Earnings Intelligence
Next Earnings
Estimated June 2026 (for Q1 2026)
Surprise Probability
Medium-High, given the significant Q4 2025 miss against estimates and recent negative operational news.
Historical Earnings Pattern
Historically sensitive to clinical trial and regulatory news; the recent Q4 2025 earnings miss resulted in analyst PT cuts, suggesting a negative market reaction to misses and operational setbacks.
Key Metrics to Watch
Competitive Position
Top Competitor
Not specified in provided data.
Market Share Trend
Gaining, if RGX-314 is approved, could establish early market leadership in specific gene therapy indications for wet AMD.
Valuation vs Peers
Difficult to compare without specific peer valuation metrics; current valuation heavily relies on future pipeline success and is subject to high volatility typical for early-stage biotech.
Competitive Advantages
- •Proprietary NAV AAV gene therapy platform and associated intellectual property
- •Strategic partnership with AbbVie for commercialization and financial backing of RGX-314
- •Advanced clinical pipeline with lead assets targeting large indications (wet AMD, Duchenne)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive RGNX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated June 2026)
- •Potential FDA PDUFA for RGX-314 (wet AMD) - timing uncertain post clinical holds, but previous BLA submission was a key milestone
- •Resolution or clarity on the FDA clinical holds for RGX-111 and RGX-121
Medium-Term (6-18 months)
- •RGX-202 (Duchenne) pivotal data in Q2 2026
- •RGX-314 (wet AMD) pivotal data in Q4 2026 (likely further data/indications)
- •Commercial launch and ramp-up of RGX-314 if approved
Long-Term (18+ months)
- •Expansion of NAV AAV platform into new therapeutic areas beyond current lead programs
- •Continued royalty streams from partnered assets (e.g., Zolgensma)
- •Achievement of profitability through successful commercialization of lead assets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for RGNX?
- ✓
FDA approval status and PDUFA date for RGX-314 (wet AMD)
- ✓
Resolution or lifting of clinical holds on RGX-111 and RGX-121
- ✓
Progress and data readout for RGX-202 (Duchenne) in Q2 2026
- ✓
Trends in cash burn and any new financing activities/dilution
Bull Case Analysis
See what could go right with Premium
Competing with RGNX
See how Regenxbio Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Regenxbio Inc RGNX | — | 7.0 | -2.3 | $170.4M | -113.8% | 104.6% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Regenxbio Inc (RGNX)?
As of March 23, 2026, Regenxbio Inc has a DVR Score of 7.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does Regenxbio Inc use?
RGNX is the ticker symbol for Regenxbio Inc. The company trades on the NMS.
What is the risk level for RGNX stock?
Our analysis rates Regenxbio Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of RGNX?
Regenxbio Inc currently has a price-to-earnings (P/E) ratio of -2.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Regenxbio Inc's revenue growing?
Regenxbio Inc has reported revenue growth of 104.6%. The company is showing strong top-line momentum.
Is RGNX stock profitable?
Regenxbio Inc has a profit margin of -113.8%. The company is currently unprofitable.
How often is the RGNX DVR analysis updated?
Our AI-powered analysis of Regenxbio Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 23, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RGNX (Regenxbio Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.